Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL811051 | 0.59 | — | — | |
| SCHEMBL6336560 | 0.59 | — | — | |
| SCHEMBL3437221 | 0.59 | — | — | |
| SCHEMBL170169 | 0.57 | — | — | |
| SCHEMBL11121127 | 0.57 | NLRP3 (0.30) | NLRP3 | |
| SCHEMBL4872030 | 0.56 | — | — | |
| SCHEMBL14193652 | 0.56 | — | — | |
| SCHEMBL3720483 | 0.52 | — | — | |
| SCHEMBL10746016 | 0.52 | — | — | |
| SCHEMBL9858372 | 0.50 | MGAM (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120137152-A | Method for preparing succinic acid polyol ester and polycondensate thereof | 上海师范大学 | 2025-06-13 | — | — | CN | claimed |
| US-7399878-B2 | Pharmaceutical compounds | NICOX S.A. (FR) | 2008-07-15 | — | — | US | claimed |
| US-20070197499-A1 | Pharmaceutical compounds | NICOX S.A. | 2007-08-23 | — | — | US | claimed |
| US-7186753-B1 | Pharmaceutical compounds | NICOX S.A. (FR) | 2007-03-06 | — | — | US | claimed |
| JP-2003515526-A | — | — | 2003-05-07 | — | — | JP | claimed |
| EP-1252133-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2002-10-30 | — | — | EP | claimed |
| WO-2001012584-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2001-02-22 | — | — | WO | claimed |
| CN-120137152-A | Method for preparing succinic acid polyol ester and polycondensate thereof | 上海师范大学 | 2025-06-13 | — | — | CN | disclosed |
| CN-120059153-A | Method and process system for preparing poly (succinate) polyester by taking maleic anhydride and/or derivatives thereof as raw materials | 上海师范大学 | 2025-05-30 | — | — | CN | disclosed |
| US-7789958-B2 | Non-toxic corrosion-protection pigments based on manganese | UNIVERSITY OF DAYTON (US) | 2010-09-07 | — | — | US | disclosed |
| US-7759392-B2 | Pharmaceutical compounds | NICOX S.A. (FR) | 2010-07-20 | — | — | US | disclosed |
| US-20090170941-A1 | Pharmaceutical Compounds | NICOX S.A. (FR) | 2009-07-02 | — | — | US | disclosed |
| US-7422793-B2 | Non-toxic corrosion-protection rinses and seals based on rare earth elements | UNIVERSITY OF DAYTON (US) | 2008-09-09 | — | — | US | disclosed |
| WO-2004065305-A1 | NON-TOXIC CORROSION-PROTECTION PIGMENTS BASED ON MANGANESE | UNIVERSITY OF DAYTON (US) | 2004-08-05 | — | — | WO | disclosed |
| US-20040104377-A1 | Non-toxic corrosion-protection pigments based on rare earth elements | UNIVERSITY OF DAYTON | 2004-06-03 | — | — | US | disclosed |
| US-20040020568-A1 | Non-toxic corrosion-protection conversion coats based on rare earth elements | DAYTON, UNIVERSITY OF | 2004-02-05 | — | — | US | disclosed |
| US-20040016910-A1 | Non-toxic corrosion-protection rinses and seals based on rare earth elements | DAYTON, UNIVERSITY OF | 2004-01-29 | — | — | US | disclosed |
| US-20040011252-A1 | Non-toxic corrosion-protection pigments based on manganese | UNIVERSITY OF DAYTON | 2004-01-22 | — | — | US | disclosed |
| EP-1252133-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2002-10-30 | — | — | EP | disclosed |
| WO-2001012584-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197499-A1 | Pharmaceutical compounds | NR0B2, NR0B1, CYP11B2 | NLRP3 3616/4885 |
| US-20090170941-A1 | Pharmaceutical Compounds | NR0B2, NR0B1, CYP11B2 | NLRP3 3718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.